Immunotherapy engagement in pancreatic adenocarcinoma: Provisional results of iLSTA study- Durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma.

被引：0
|
作者：
Dean, Andrew Peter
Johansson, Mikael
Yusoff, Ian
Rao, Samarth
Sparrow, Susan
Kumarasinghe, Priyanthi
Navadgi, Suresh
Watanabe, Yuki
Webber, Laurence
Grew, Jenny
Fitzgerald, Shane
Comito, Olivia Rose
机构：
[1] St John God Subiaco Hosp, Subiaco, Australia
[2] Dept Upper GI Surg, Nedlands, Australia
[3] Sir Charles Gairdner Hosp, Nedlands, Australia
[4] Australian Clin Labs, Subiaco, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A retrospective study of gemcitabine with nab-paclitaxel as third-line retreatment in advanced pancreatic adenocarcinoma
    McSweeney, T.
    Das, A.
    O'Mahony, A.
    O'Tighearnaigh, F.
    O'Byrne, L.
    Feely, M.
    Passmore, E.
    Keane, S.
    Lanigan, S.
    Fitzgerald, S.
    Browne, T.
    De Beer, V.
    Dean, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S126 - S126
  • [22] Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma-results of a match-pair analysis
    Ramaswamy, Anant
    Shah, Darshit
    Bhargava, Prabhat
    Srinivas, Sujay
    Kannan, Sadhana
    Shah, Minit
    Suman, Mannavi
    Das, Shasanka
    Trikha, Mehak
    Ostwal, Vikas
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2023, 157 (01) : 57 - +
  • [23] Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Mozzillo, Eleonora
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    CANCERS, 2021, 13 (19)
  • [24] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [25] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [26] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [27] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [28] Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis
    Takashi Kaneko
    Kazuya Sugimori
    Yuichiro Tozuka
    Taito Fukushima
    Kazuya Okada
    Hiroyuki Oka
    Hiroshi Okazaki
    Shin Maeda
    Clinical Journal of Gastroenterology, 2019, 12 : 484 - 489
  • [29] Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma
    Azmi, Asfar S.
    Khan, Husain Yar
    Muqbil, Irfana
    Aboukameel, Amro
    Neggers, Jasper E.
    Daelemans, Dirk
    Mahipal, Amit
    Dyson, Gregory
    Kamgar, Mandana
    Al-Hallak, Mohammad Najeeb
    Tesfaye, Anteneh
    Kim, Steve
    Shidham, Vinod
    Mohammad, Ramzi M.
    Philip, Philip A.
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1338 - 1348
  • [30] Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis
    Kaneko, Takashi
    Sugimori, Kazuya
    Tozuka, Yuichiro
    Fukushima, Taito
    Okada, Kazuya
    Oka, Hiroyuki
    Okazaki, Hiroshi
    Maeda, Shin
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2019, 12 (05) : 484 - 489
12345